Innovation Pharmaceuticals Inc.

ipharminc.com

Innovation Pharmaceuticals, Inc. is a clinical stage biotechnology company, which engages in the development of therapies with anti-infective, oncology, anti-inflammatory, and dermatology applications. The company is headquartered in Wakefield, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2007-04-02. The Company’s lead drug candidate, Brilacidin, is in a class of compounds called defensin-mimetics, small compounds that mimic the structure and function of defensins, also known as host defense peptides. The firm is primarily focused on business development for the advancement of Brilacidin in the treatment of infectious diseases and oral mucositis. Its ongoing activities include Brilacidin drug manufacturing, scientific report writing, and supportive research activities. Brilacidin is also developed as a treatment in more extensive forms of inflammatory bowel disease (IBD). The company is engaged in developing an image guided surgical laser platform, through BT BeaMedical Technologies Ltd. The company is also engaged in business development and licensing initiatives with specialty and global pharmaceutical companies.